Neuberg Readies for IPO in FY28, to Seek Up to Rs 4,000 Cr

New Delhi, India Jul 7, 2026 ALN: Mumbai: Neuberg Diagnostics is preparing for an initial public offering (IPO) in fiscal year 2028, with plans to raise approximately ₹3,500-4,000 crore, according to founder and chairman GSK Velu. This announcement comes at a time when the Indian healthcare sector is experiencing significant growth, driven by increasing demand for diagnostic services and advancements in medical technologies.

The Chennai-based diagnostics company aims to secure ₹500 crore in a pre-IPO funding round over the next three to six months. This funding will be directed towards financing four to five acquisitions as part of its pan-India expansion strategy. The move to acquire other companies is indicative of the competitive landscape in the diagnostics industry, where consolidation is becoming increasingly common as companies seek to enhance their service offerings and geographical reach.

Velu stated, "The plan is to prepare for an IPO in FY28, potentially between April and September, depending on market conditions and readiness. The IPO itself could be in the range of ₹3,500 crore to ₹4,000 crore. It is likely to include both a fresh issue and a secondary component for the existing private equity investor. Prior to the IPO, we may invest around ₹700 crore to ₹1,000 crore across acquisitions and growth initiatives." This approach not only highlights Neuberg's ambitious growth trajectory but also underscores the importance of strategic investments in maintaining a competitive edge in the evolving healthcare landscape.

Neuberg specializes in new-generation diagnostic technologies, focusing on genomics testing and longevity programs as key growth pillars. Genomics testing is a rapidly growing field that allows for more personalized and precise medical care, tailoring treatments to individual genetic profiles. Velu expressed confidence in the company's potential, stating, "We believe we can be in a strong position to emerge as the number two player. Of course, that also depends on how the broader market and competitors evolve." This ambition to become a leading player in the diagnostics sector reflects the broader trends in healthcare, where personalized medicine is gaining traction.

In FY26, the gross revenue of Neuberg was reported at ₹1,400 crore, indicating a solid financial foundation as the company prepares for its IPO. This revenue figure places Neuberg in a competitive position within the diagnostics market, which is characterized by a mix of established players and new entrants vying for market share.

As part of its expansion into western India, Neuberg is launching a preventive health center in Mumbai, which will offer advanced tests based on genetics, pathology, and radiology. Preventive healthcare is increasingly recognized as a crucial component of overall health management, as it focuses on early detection and intervention to mitigate the risks of serious illnesses. Velu noted that new-generation tests are expected to contribute 25% of revenue within three years, up from 15% currently. "Our immediate focus is on Mumbai, Maharashtra, Delhi, and the NCR region," he added. This geographic focus aligns with the company’s strategy to tap into high-density urban areas where demand for advanced diagnostic services is on the rise.

Kavya Velu, executive director and president of Neuberg, emphasized the company's commitment to genomics and advanced pathology. She stated, "At the same time, we have been bringing in partners with radiology capabilities because we believe the future of healthcare will be preventive, predictive, and personalized." This vision reflects a broader shift in healthcare towards integrated service models that combine various diagnostic modalities to provide comprehensive care. By collaborating with partners in radiology, Neuberg is positioning itself to offer a holistic approach to patient care, which is increasingly demanded by both healthcare providers and patients.

Neuberg's strategic initiatives and focus on innovative diagnostic technologies position it well for future growth in the competitive healthcare sector. The emphasis on genomics and preventive health aligns with global trends that prioritize personalized medicine and proactive health management. As the company prepares for its IPO, it will need to navigate various challenges, including regulatory hurdles, market competition, and the need to continuously innovate in a rapidly evolving industry.

In the context of the Indian healthcare market, which is projected to grow significantly in the coming years, Neuberg's expansion plans are timely. The market is witnessing increased investment in healthcare infrastructure, driven by both private and public sector initiatives. As healthcare spending rises, driven by a growing middle class and increasing health awareness, companies like Neuberg are well-positioned to capitalize on these trends.

Moreover, the ongoing global pandemic has underscored the importance of robust diagnostic capabilities, leading to a heightened focus on testing and preventive care. Companies that can innovate and adapt to changing consumer demands will likely thrive in this environment. Neuberg's commitment to advanced diagnostics and personalized healthcare solutions reflects an understanding of these dynamics.

Looking ahead, the success of Neuberg's IPO will depend not only on its financial performance but also on its ability to execute its strategic vision effectively. Investors will be watching closely to see how the company navigates its expansion plans, integrates acquisitions, and continues to innovate in the diagnostic space. The upcoming IPO could serve as a significant milestone for Neuberg, potentially enabling it to raise the necessary capital to fuel its growth ambitions and solidify its position in the market.

In conclusion, Neuberg Diagnostics is setting the stage for a significant entry into the public with its planned IPO in FY28. By focusing on strategic acquisitions, innovative diagnostic technologies, and expanding its geographical footprint, the company is positioning itself for success in a competitive and rapidly evolving healthcare landscape. As the demand for advanced diagnostic services continues to grow, Neuberg's efforts to enhance its offerings and improve patient care will be critical in determining its future trajectory.